United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Terns Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -29.56% | -0.09% | -0.09% | -0.09% | -0.09% | -0.09% |
|---|---|---|---|---|---|---|
| ROA | -28.1% | -0.09% | -0.09% | -0.09% | -0.09% | -0.09% |
| Total Assets | $363,929.00K | $363,929.00K | $363,929.00K | $363,929.00K | $363,929.00K | $363,929.00K |
| Net Income | -$88,853.00K | -$319.00K | -$319.00K | -$319.00K | -$319.00K | -$319.00K |